For the twelve months ended Sep 30, 2026, Diebold Nixdorf Incorporated reported $3.92B of revenue and $76.70M of net income.
DBD revenueQ3 2026$994.30M
- Quarter YoY
- +5.2%
- QoQ
- +6.8%
- FY YoY
- +1.5%
- 5Y CAGR
- -0.5%
- 10Y CAGR
- +4.6%
DBD revenue was $994.30M in fiscal Q3 2026 (ended Sep 30, 2026), up 5.2% from a year earlier and up 6.8% from the prior quarter. For the full fiscal 2025 it was $3.81B, up 1.5% from fiscal 2024. Compound annual growth was -0.5% over 5 years and +4.6% over 10 years.
DBD net incomeQ3 2026$6.60M
- Quarter YoY
- -83.9%
- QoQ
- -57.4%
- 10Y CAGR
- +2.5%
DBD net income was $6.60M in fiscal Q3 2026 (ended Sep 30, 2026), down 83.9% from a year earlier and down 57.4% from the prior quarter. For the full fiscal 2025 it was $94.60M, compared with -$16.50M in fiscal 2024. Compound annual growth was +2.5% over 10 years.
DBD EPSQ3 2026$0.19
- Quarter YoY
- -82.9%
- QoQ
- -56.8%
DBD diluted EPS was $0.19 in fiscal Q3 2026 (ended Sep 30, 2026), down 82.9% from a year earlier and down 56.8% from the prior quarter. For the full fiscal 2025 it was $2.54, compared with -$0.44 in fiscal 2024.
Source: XBRL data Diebold Nixdorf Incorporated files with the SEC, latest filing dated Oct 28, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.